methyldopa has been researched along with Disease Exacerbation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bergman, H; El-Sayeh, HG; Rathbone, J; Soares-Weiser, K | 1 |
| Adam, I; Elhassan, EM; Habour, AB; Mirghani, OA | 1 |
1 review(s) available for methyldopa and Disease Exacerbation
| Article | Year |
|---|---|
Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia.
Topics: Adrenergic Uptake Inhibitors; Anti-Dyskinesia Agents; Antipsychotic Agents; Celiprolol; Disease Progression; Dopamine Antagonists; Dyskinesia, Drug-Induced; Haloperidol; Humans; Methyldopa; Randomized Controlled Trials as Topic; Reserpine; Tetrabenazine; Tiapamil Hydrochloride | 2018 |
1 trial(s) available for methyldopa and Disease Exacerbation
| Article | Year |
|---|---|
Methyldopa versus no drug treatment in the management of mild pre-eclampsia.
Topics: Abruptio Placentae; Adult; Antihypertensive Agents; Apgar Score; Birth Weight; Delivery, Obstetric; Disease Progression; Eclampsia; Female; Fetal Death; Fetal Growth Retardation; Humans; Methyldopa; Organ Size; Parity; Pediatrics; Placenta; Pre-Eclampsia; Pregnancy; Pregnancy Outcome; Pregnancy Trimester, Third; Referral and Consultation; Severity of Illness Index; Treatment Outcome | 2002 |